Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 65 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab for previously untreated,hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line	Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride)	Biliary tract cancer	Gastrointestinal Cancer	2021	View \| Download
Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download
Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer	5-Fluorouracil , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Leucovorin , Oxaliplatin	Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2023	View \| Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Encorafenib in combination with binimetinib and cetuximab for BRAF V600E mutant metastatic colorectal cancer	Binimetinib (MEK162; MEK-162; ARRY-162) , Cetuximab (Erbitux; STI-001) , Encorafenib (LGX818)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2019	View \| Download
Eryaspase in addition to chemotherapy for treating advanced or metastatic pancreatic cancer – second-line	Eryaspase (Graspa; ERY001) , FOLFOX4 , Gemcitabine (Gemzar; gemcitabine hydrochloride)	Pancreatic cancer	Gastrointestinal Cancer	2020	View \| Download